diff --git a/data/approvals/sample-approval-1.json b/data/approvals/sample-approval-1.json new file mode 100644 index 0000000..44c7538 --- /dev/null +++ b/data/approvals/sample-approval-1.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Amiodarone", + "indication": "Antiarrhythmic", + "approval_date": "2023-08-15", + "regulatory_body": "FDA", + "status": "Approved", + "notes": "Fast track approval due to critical need in arrhythmia management." +} diff --git a/data/approvals/sample-approval-2.json b/data/approvals/sample-approval-2.json new file mode 100644 index 0000000..49962b5 --- /dev/null +++ b/data/approvals/sample-approval-2.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Taltz", + "indication": "Plaque Psoriasis", + "approval_date": "2016-03-22", + "regulatory_body": "EMA", + "status": "Approved", + "notes": "Biologic drug targeting IL-17A. Approved for moderate to severe cases." +} diff --git a/data/approvals/sample-approval-3.json b/data/approvals/sample-approval-3.json new file mode 100644 index 0000000..a36a0ba --- /dev/null +++ b/data/approvals/sample-approval-3.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Zocor", + "indication": "Hypercholesterolemia", + "approval_date": "1991-12-16", + "regulatory_body": "FDA", + "status": "Approved (Generic Available)", + "notes": "HMG-CoA reductase inhibitor (statin). Now widely used as a generic (Simvastatin)." +} diff --git a/data/pipeline/sample-pipeline-1.json b/data/pipeline/sample-pipeline-1.json new file mode 100644 index 0000000..4994200 --- /dev/null +++ b/data/pipeline/sample-pipeline-1.json @@ -0,0 +1,8 @@ +{ + "candidate_id": "OPRX-402", + "target_disease": "Infectious Disease", + "current_phase": "Phase II", + "start_date": "2023-05-10", + "expected_completion": "2025-11-01", + "notes": "Testing efficacy against multi-drug resistant bacterial strains." +} diff --git a/data/pipeline/sample-pipeline-2.json b/data/pipeline/sample-pipeline-2.json new file mode 100644 index 0000000..696e678 --- /dev/null +++ b/data/pipeline/sample-pipeline-2.json @@ -0,0 +1,10 @@ + +{ + "candidate_id": "OPRX-510", + "target_disease": "Alzheimer's Disease", + "current_phase": "Phase I (Pre-IND)", + "start_date": "2024-01-25", + "expected_completion": "2026-06-30", + "notes": "Focus on early-stage amyloid plaque reduction and safety profile." +} + diff --git a/data/pipeline/sample-pipeline-3.json b/data/pipeline/sample-pipeline-3.json new file mode 100644 index 0000000..f17c5c9 --- /dev/null +++ b/data/pipeline/sample-pipeline-3.json @@ -0,0 +1,10 @@ + +{ + "candidate_id": "OPRX-601", + "target_disease": "Type 2 Diabetes", + "current_phase": "Phase III (Recruiting)", + "start_date": "2022-09-01", + "expected_completion": "2024-12-31", + "notes": "Large multi-site international trial focusing on A1C reduction and cardiovascular outcomes." +} + diff --git a/data/pricing/sample-pricing-1.json b/data/pricing/sample-pricing-1.json new file mode 100644 index 0000000..32d507a --- /dev/null +++ b/data/pricing/sample-pricing-1.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Amiodarone", + "unit_of_sale": "100mg tablet (bottle of 30)", + "wholesale_cost": 45.00, + "list_price": 99.99, + "manufacturer_rebate_rate": 0.15, + "notes": "Pricing reflects competitive landscape for generics." +} diff --git a/data/pricing/sample-pricing-2.json b/data/pricing/sample-pricing-2.json new file mode 100644 index 0000000..a78cbe4 --- /dev/null +++ b/data/pricing/sample-pricing-2.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Taltz", + "unit_of_sale": "80mg/mL autoinjector (single unit)", + "wholesale_cost": 4500.00, + "list_price": 5800.00, + "manufacturer_rebate_rate": 0.28, + "notes": "Premium pricing due to specialized biologic status and limited competition." +} diff --git a/data/pricing/sample-pricing-3.json b/data/pricing/sample-pricing-3.json new file mode 100644 index 0000000..a8f6d6b --- /dev/null +++ b/data/pricing/sample-pricing-3.json @@ -0,0 +1,8 @@ +{ + "drug_name": "OPRX-601", + "unit_of_sale": "200mg capsules (bottle of 60)", + "wholesale_cost": 150.00, + "list_price": 275.00, + "manufacturer_rebate_rate": 0.05, + "notes": "Planned launch price, pending Phase III success and competitive analysis." +} diff --git a/data/safety/sample-safety-1.json b/data/safety/sample-safety-1.json new file mode 100644 index 0000000..3151eb4 --- /dev/null +++ b/data/safety/sample-safety-1.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Amiodarone", + "report_id": "SA-2023-001", + "severity": "Moderate", + "adverse_event": "Thyroid Dysfunction", + "date_reported": "2024-01-20", + "actions_taken": "Issued updated black box warning." +} diff --git a/data/safety/sample-safety-2.json b/data/safety/sample-safety-2.json new file mode 100644 index 0000000..d605496 --- /dev/null +++ b/data/safety/sample-safety-2.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Taltz", + "report_id": "SA-2024-002", + "severity": "Mild", + "adverse_event": "Injection Site Reaction", + "date_reported": "2024-03-01", + "actions_taken": "Updated patient counseling materials regarding proper injection technique." +} diff --git a/data/safety/sample-safety-3.json b/data/safety/sample-safety-3.json new file mode 100644 index 0000000..2d6f2a6 --- /dev/null +++ b/data/safety/sample-safety-3.json @@ -0,0 +1,8 @@ +{ + "drug_name": "Zocor", + "report_id": "SA-2024-003", + "severity": "Severe", + "adverse_event": "Rhabdomyolysis", + "date_reported": "2024-04-10", + "actions_taken": "Restricted dosage for patients with renal impairment." +}